Toggle Offcanvas
...
 
Dolutegravir Tenders

Dolutegravir Tenders

View Dolutegravir tenders, RFPs and contracts. Bid on readily available Dolutegravir tenders with the best and most comprehensive tendering platform, since 2002.
Dolutegravir is an antiretroviral drug used in the treatment of HIV/AIDS, often combined with other medications. It blocks the HIV enzyme integrase, preventing the virus from replicating and lowering the viral load in the body.

Bidding for Dolutegravir tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Dolutegravir.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Dolutegravir market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Dolutegravir tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

32 Live Notices for Dolutegravir Tenders

Showing 1 to 20

Open House Pharmaceutical Discounts On The Active Ingredient Lamivudine And Dolutegravir, Atc J05Ar25
country Germany
posting date14 Jul 2025
deadline30 Jun 2027
Open House Pharmaceutical Discounts On The Active Ingredient Lamivudine And Dolutegravir, Atc J05Ar25
country Germany
posting date14 Jul 2025
deadline30 Jun 2027
Open House Pharmaceutical Discount Contracts For The Active Ingredient Lamivudine, Abacavir And Dolutegravir, Atc J05Ar13
country Germany
posting date14 Jul 2025
deadline30 Jun 2027
Open House Pharmaceutical Discount Contracts For The Active Ingredient Lamivudine, Abacavir And Dolutegravir, Atc J05Ar13
country Germany
posting date14 Jul 2025
deadline30 Jun 2027
Open House Pharmaceutical Discounts On The Active Ingredient Lamivudine And Dolutegravir, Atc J05Ar25
country Germany
posting date13 Jul 2025
deadline30 Jun 2027
Open House Pharmaceutical Discount Contracts For The Active Ingredient Lamivudine, Abacavir And Dolutegravir, Atc J05Ar13
country Germany
posting date13 Jul 2025
deadline30 Jun 2027
Hiv 3 Drugs
country Romania
posting date09 Jul 2025
deadline19 Aug 2025
Hiv 3 Drugs
country Romania
posting date08 Jul 2025
deadline19 Aug 2025
Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V On The Active Ingredient Lamivudin + Abacavir + Dolutegravir, Atc J05Ar13 For The Time 01.07.2025 - 30.06.2027
country Germany
posting date20 May 2025
deadline05 May 2027
Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V On The Active Ingredient Dolutegravir + Rilpivirin, Atc J05Ar21 For The Time 01.07.2025 - 30.06.2027
country Germany
posting date20 May 2025
deadline05 May 2027
Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V On The Active Ingredient Lamivudin + Dolutegravir, Atc J05Ar25 For The Period 01.07.2025 - 30.06.2027
country Germany
posting date20 May 2025
deadline05 May 2027
Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V On The Active Ingredient Lamivudin + Dolutegravir, Atc J05Ar25 For The Period 01.07.2025 - 30.06.2027
country Germany
posting date20 May 2025
deadline05 May 2027
Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V On The Active Ingredient Dolutegravir + Rilpivirin, Atc J05Ar21 For The Time 01.07.2025 - 30.06.2027
country Germany
posting date20 May 2025
deadline05 May 2027
Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V On The Active Ingredient Lamivudin + Abacavir + Dolutegravir, Atc J05Ar13 For The Time 01.07.2025 - 30.06.2027
country Germany
posting date20 May 2025
deadline05 May 2027
Open House Pharmaceutical Discounts On The Active Ingredient Dolutegravir, Atc J05Aj03
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Pharmaceutical Discounts On The Active Ingredient Dolutegravir, Atc J05Aj03
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Pharmaceutical Discounts On The Active Ingredient Dolutegravir, Atc J05Aj03
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Original Discount Agreements 2025-06 - Dolutegravir
country Germany
posting date22 Jan 2025
deadline28 Feb 2027
Open House Original Discount Agreements 2025-07 - Lamivudine/Abacavir/Dolutegravir (Active Ingredient Combination)
country Germany
posting date22 Jan 2025
deadline28 Feb 2027
Open House Original Discount Agreements 2025-07 - Lamivudine/Abacavir/Dolutegravir (Active Ingredient Combination)
country Germany
posting date22 Jan 2025
deadline28 Feb 2027

Share Share this page